Skip to main content


Schizophrenia and personality disorders had the highest burdens of disability among individuals with mental health or substance use disorders, according to a new analysis published in The Lancet Psychiatry.
In this Q&A, corresponding author Christoph U. Correll, MD, explains his meta-analysis that found the presence of metabolic syndrome is significantly associated with cognitive dysfunction in individuals with schizophrenia.
Positive and Negative Syndrome Scale total scores dropped an additional 11.6 points in patients with schizophrenia who received combination xanomeline-trospium, compared with placebo, according to a published study.
Switching to aripiprazole or ziprasidone could improve weight and other cardiometabolic outcomes in patients with serious mental illness, according to a systematic review and meta-analysis published online in Schizophrenia Bulletin.
When choosing an antipsychotic for acute treatment of psychosis, evaluating the drug's side effects is an important step, Dr. Stephen Marder said at a 26th Annual National Psychopharmacology Update session.
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications?
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top